Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Etivelcabtagene Erigedleucel

Cell therapy (CAR-T) · Kills target cells, directed at CD20 (MS4A1) and CD22 · developed by Cellectis

Phase 1/2 Most advanced trial

CLLS Developer

1 Registered trials

What is Etivelcabtagene Erigedleucel?

Etivelcabtagene erigedleucel is an allogeneic, off-the-shelf CAR-T cell product made from T-lymphocytes engineered with TALEN gene editing to express chimeric antigen receptors specific for CD20 and CD22. The CAR-T cells are designed to recognize and kill CD20- and CD22-expressing tumor cells, and are being studied in B-cell non-Hodgkin lymphoma. The TRAC and CD52 genes are knocked out to limit graft-versus-host disease risk and to resist anti-CD52 antibody treatment used in preconditioning.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: UCART20x22
Drug type: Cell therapy (CAR-T)
Targets: CD20 (MS4A1) (antigen), CD22 (antigen)
Mechanism: Kills target cells, directed at CD20 (MS4A1) and CD22
Therapy area: Oncology
Developer: Cellectis S.A. (CLLS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: E4X5PXM3XS

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05607420	Phase 1/2	B-cell Non-Hodgkin Lymphoma (B-NHL)	Recruiting	CLLS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Non-Hodgkin Lymphoma (B-NHL)

Other drugs acting on MS4A1 / CD22

AZD5492 Phase 1/2 Epratuzumab-cys-tesirine Phase 1/2 Imvotamab Phase 1/2 Odronextamab Phase 2/3 TL011 Phase 1

More from Cellectis

Lasmecabtagene Timgedleucel Phase 1/2 UCART123 Phase 1 UCART123v1.2 Phase 1 UCARTCS1A Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLLS page.

Follow CLLS, the company behind Etivelcabtagene Erigedleucel

See CLLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLLS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z